5081-48-1 | Ellipticine hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$50.00	$35.00
5mg	98%	in stock	$84.00	$59.00
10mg	98%	in stock	$124.00	$87.00
25mg	98%	in stock	$287.00	$201.00
50mg	98%	in stock	$489.00	$342.00
100mg	98%	in stock	$870.00	$609.00
250mg	98%	in stock	$1,479.00	$1,035.00

Description

• Catalog Number: AX64616
• Chemical Name: Ellipticine hydrochloride
• CAS Number: 5081-48-1
• Molecular Formula: C17H15ClN2
• Molecular Weight: 282.7674
• MDL Number: MFCD00050600
• SMILES: CC1=C2C(=C(C3=C1C=CN=C3)C)C4=CC=CC=C4N2.Cl
• NSC Number: 133891

Computed Properties

• Complexity: 342
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 1
• Hydrogen Bond Donor Count: 2

Literature

• Comparative in vitro and in vivo antimalarial activity of the indole alkaloids ellipticine, olivacine, cryptolepine and a synthetic cryptolepine analog.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20121215

• Photophysical and photodynamical study of ellipticine: an anticancer drug molecule in bile salt modulated in vitro created liposome.

  Physical chemistry chemical physics : PCCP 20121128

• Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis.

  Nanomedicine : nanotechnology, biology, and medicine 20120701

• Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids.

  Chemical reviews 20120613

• Tolbutamide hydroxylation by hepatic microsomes from Atlantic salmon (Salmo salar L.).

  Molecular biology reports 20120601

• Study of DNA-ellipticine interaction by capillary electrophoresis with laser-induced fluorescence detection.

  Electrophoresis 20120601

• Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20120601

• Molecular binding of self-assembling peptide EAK16-II with anticancer agent EPT and its implication in cancer cell inhibition.

  Journal of controlled release : official journal of the Controlled Release Society 20120530

• Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells.

  Cancer science 20120201

• Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo.

  International journal of nanomedicine 20120101

• Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.

  PloS one 20120101

• Ellipticine induces apoptosis in human endometrial cancer cells: the potential involvement of reactive oxygen species and mitogen-activated protein kinases.

  Toxicology 20111118

• Synthesis and antiproliferative activity of some ellipticine-like 11H-pyrido[a]carbazole derivatives.

  ChemMedChem 20111004

• Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.

  Biochemical pharmacology 20110915

• Dual fluorescence of ellipticine: excited state proton transfer from solvent versus solvent mediated intramolecular proton transfer.

  The journal of physical chemistry. A 20110825

• A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells.

  Investigational new drugs 20110801

• Ellipticine-aimed polymer-conjugated auger electron emitter: multistage organelle targeting approach.

  Bioconjugate chemistry 20110615

• Release of hydrophobic anticancer drug from a newly designed self-assembling peptide.

  Molecular bioSystems 20110601

• Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells.

  Apoptosis : an international journal on programmed cell death 20110301

• Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.

  Plant signaling & behavior 20110301

• Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.

  Biochimica et biophysica acta 20110101

• Synthesis of new 1-phenyl-6H-pyrido[4,3-b]carbazole derivatives with potential cytostatic activity.

  Acta poloniae pharmaceutica 20110101

• Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.

  Neuro endocrinology letters 20110101

• Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2.

  Cancer research 20101201

• Glycosylation protects proteins against free radicals generated from toxic xenobiotics.

  Toxicological sciences : an official journal of the Society of Toxicology 20101001

• Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

  Assay and drug development technologies 20100801

• Labdane-type diterpenes from Hedychium gardnerianum with potent cytotoxicity against human small cell lung cancer cells.

  Phytotherapy research : PTR 20100701

• CYP1A inhibition in fish gill filaments: a novel assay applied on pharmaceuticals and other chemicals.

  Aquatic toxicology (Amsterdam, Netherlands) 20100131

• Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.

  Neuro endocrinology letters 20100101

• The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells.

  Cancer biology & therapy 20091101

• Identification of new 2-amino-3-methylimidazo[4,5-f]quinoline urinary metabolites from beta-naphthoflavone-treated mice.

  Drug metabolism and disposition: the biological fate of chemicals 20090801

• Docking studies on DNA-ligand interactions: building and application of a protocol to identify the binding mode.

  Journal of chemical information and modeling 20090801

• Synthesis and cytotoxic activity of 5,6-heteroaromatically annulated pyridine-2,4-diamines.

  Bioorganic & medicinal chemistry 20090701

• The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.

  Biochemical pharmacology 20090501

• DNA binding ellipticine analogues: synthesis, biological evaluation, and structure-activity relationships.

  ChemMedChem 20090301

• Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20090201

• Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.

  Neuro endocrinology letters 20090101

• Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73.

  Cancer biology & therapy 20081201

• Computer simulations reveal a novel nucleotide-type binding orientation for ellipticine-based anticancer c-kit kinase inhibitors.

  Biochemistry 20080930

• Synthesis and anticancer activity of new 1-substituted-6H-pyrido[4,3-b]carbazole derivatives.

  Archiv der Pharmazie 20080601

• A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization.

  Apoptosis : an international journal on programmed cell death 20080301

• Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.

  Toxicology and applied pharmacology 20080201

• Restoration of p53 to limit tumor growth.

  Current opinion in oncology 20080101

• Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine.

  PloS one 20080101

• The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.

  Cancer letters 20070718

• Density-functional, density-functional tight-binding, and wave function calculations on biomolecular systems.

  The journal of physical chemistry. A 20070705

• Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.

  Toxicology 20070701

• 8-Methyl-4-(3-diethylaminopropylamino) pyrimido [4',5';4,5] thieno (2,3-b) quinoline (MDPTQ), a quinoline derivate that causes ROS-mediated apoptosis in leukemia cell lines.

  Toxicology and applied pharmacology 20070701

• Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.

  Cancer research 20070615

• Abundance of aryl hydrocarbon receptor potentiates benzo[a]pyrene-induced apoptosis in Hepa1c1c7 cells via CYP1A1 activation.

  Toxicology 20070603

• Pattern recognition methods investigation of ellipticines structure-activity relationships.

  Journal of molecular graphics & modelling 20070301

• Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.

  International journal of cancer 20070115

• Thermotropic phase behavior of DPPC liposome systems in the presence of the anti-cancer agent 'Ellipticine'.

  European biophysics journal : EBJ 20061201

• Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.

  Neuro endocrinology letters 20061201

• Solvent effect on the photophysical properties of the anticancer agent ellipticine.

  The journal of physical chemistry. A 20061012

• Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.

  General physiology and biophysics 20060901

• Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20060701

• Lipid model membranes for drug interaction study.

  European biophysics journal : EBJ 20060501

• Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells.

  Life sciences 20060425

• Lack of CYP1A1 expression is involved in unresponsiveness of the human hepatoma cell line SK-HEP-1 to dioxin.

  Toxicology letters 20051230

• Synthesis of ellipticine: a radical cascade protocol to aryl- and heteroaryl-annulated[b]carbazoles.

  The Journal of organic chemistry 20051209

• Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.

  Chromosoma 20051201

• Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20051201

• Oxidation of an antitumor drug ellipticine by peroxidases.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20051201

• Regioselective intramolecular reactions of 2-indolylacyl radicals with pyridines: a direct synthetic entry to ellipticine quinones.

  The Journal of organic chemistry 20051028

• Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.

  Journal of medicinal chemistry 20051006

• The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction.

  Anti-cancer drugs 20050801

• The role of hydrogen bond acceptor groups in the interaction of substrates with Pdr5p, a major yeast drug transporter.

  Biochemistry 20050719

• The anticancer agent ellipticine unwinds DNA by intercalative binding in an orientation parallel to base pairs.

  Acta crystallographica. Section D, Biological crystallography 20050701

• The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells.

  Cancer letters 20050608

• Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent.

  Journal of controlled release : official journal of the Controlled Release Society 20050321

• The development of VIP-ellipticine conjugates.

  Regulatory peptides 20041215

• The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.

  Cancer research 20041115

• New indole alkaloids from the roots of Ochrosia acuminata.

  Journal of natural products 20041001

• Effect of LNA modifications on small molecule binding to nucleic acids.

  Journal of biomolecular structure & dynamics 20040601

• Synthesis and cytotoxic activity of pyranocarbazole analogues of ellipticine and acronycine.

  Chemical & pharmaceutical bulletin 20040501

• Induction of endoplasmic reticulum stress by ellipticine plant alkaloids.

  Molecular cancer therapeutics 20040401

• Extending nature's leads: the anticancer agent ellipticine.

  Current medicinal chemistry. Anti-cancer agents 20040301

• Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine.

  Journal of pharmaceutical sciences 20040101

• DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.

  International journal of cancer 20031220

• Formation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene adducts in vascular endothelia of cytochrome P4501A-induced chicken embryos.

  Environmental toxicology and chemistry 20031001

• Rescue of mutant p53 transcription function by ellipticine.

  Oncogene 20030717

• Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.

  Chemical research in toxicology 20030101

• Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.

  Mutation research 20020926

• Target cells for cytochrome p450-catalysed irreversible binding of 7,12-dimethylbenz[a]anthracene (DMBA) in rodent adrenal glands.

  Archives of toxicology 20020801

• VIP-ellipticine derivatives inhibit the growth of breast cancer cells.

  Life sciences 20020719

• Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.

  Biochemical pharmacology 20020715

• A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.

  Biochemistry 20020625

• Potent inhibition of DNA unwinding and ATPase activities of pea DNA helicase 45 by DNA-binding agents.

  Biochemical and biophysical research communications 20020607

• The chemical constituents and biological activity of essential oil of Lavandula stoechas ssp. stoechas.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20020101

• The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.

  Biochemical pharmacology 20011215

• Catalytic and immunochemical properties of hepatic cytochrome P450 1A in three avian species treated with beta-naphthoflavone or isosafrole.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20010901

• Astaxanthin accumulation in Haematococcus requires a cytochrome P450 hydroxylase and an active synthesis of fatty acids.

  FEBS letters 20010706

• Indications for the involvement of a CYP3A-like iso-enzyme in the metabolism of chlorobornane (Toxaphene) congeners in seals from inhibition studies with liver microsomes.

  Aquatic toxicology (Amsterdam, Netherlands) 20010101

• Complex formation in the indolo[2,3-b]quinolines--methylene blue systems in aqueous solutions.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20010101

• Ellipticine, uleine, apparicine, and related alkaloids.

  The Alkaloids. Chemistry and biology 20010101

• Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line.

  The Journal of biological chemistry 19881215